Core Viewpoint - The company Garden Biologics (300401) is currently in the process of constructing its "Vitamin D2 raw material project" and "Vitamin D2 preparation project," with specific progress and capacity planning to be disclosed in future announcements [1] Group 1 - The "Vitamin D2 raw material project" is under construction [1] - The "Vitamin D2 preparation project" is also in the construction phase [1] - Future announcements will provide detailed updates on progress and capacity planning [1]

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]